Close Menu

NEW YORK – Stilla Technologies announced Tuesday it will partner with ID-Solutions, a French liquid biopsy firm, to commercialize oncology detection kits. Terms of the deal were not disclosed.

The commercialization partnership covers an oncology kit line the firms call Identify, which consist of a range of ready-to-use multiplexed mutation panels that run on the Stilla Naica digital PCR system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Sponsored by

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.